Bonum Therapeutics, Inc.

SAN FRANCISCO--(BUSINESS WIRE)-- Infinimmune, a biotechnology company pioneering new methods for antibody drug discovery and development, announced today the appointment of a new independent director, Neela Patel, Ph.D., to the company's Board of Directors. Dr. Patel is a seasoned life sciences executive and experienced board member who brings decades of pharmaceutical and biotechnology industry leadership experience and strong drug development expertise, including a track record of successful U.S. and global pharmaceutical licensing deals. “We are thrilled to welcome Neela as an independent Board member,” said Dr. Wyatt McDonnell, CEO & Co-Founder, Infinimmune. “With over 25 years of leadership experience spanning drug discovery, development, strategic partnerships, and corporate development, she brings invaluable expertise to Infinimmune. Her proven track record of pipeline development and strategic collaborations will be invaluable as we continue to advance our programs and pursue new opportunities for growth.” “I am excited to join Infinimmune and contribute to its mission of identifying and developing truly human therapeutics to develop safer, more effective therapies for patients,” said Patel. “I look forward to contributing my expertise in deal-making and drug discovery to the long-term success of Infinimmune. The outstanding team and transformative platform technology position the company to build a remarkable pipeline.” Dr. Patel is a scientist and business development executive with more than 25 years of leadership experience in drug discovery & development, project & portfolio management, and pipeline development through external innovation. She is currently Chief Business Officer at Bonum Therapeutics. Prior to Bonum, she was Chief Business Development Officer at Good Therapeutics, where she co-led the Roche transaction and spinout of Bonum. Previously, as Executive Director of Corporate Development at Seagen, she played an integral role in deal sourcing and execution to build the pipeline, including agreements with Pieris and FivePrime. Her sourcing and diligence at AbbVie resulted in more than 25 executed deals including collaborations, licensing, and participation in consortia. Dr. Patel spent the first 16 years of her career in drug discovery with positions of increasing responsibility, advancing small molecules and biologics from target ID and validation through IND filing at Poniard Pharmaceuticals, Genentech, SUGEN/Pharmacia, and Roche Bioscience. Dr. Patel completed her postdoctoral training at the DNAX Research Institute after receiving her PhD in Molecular Biology from UCLA. She graduated Phi Beta Kappa from Stanford with a B.S. in Biology and a B.A. in Humanities with Honors. About Infinimmune Infinimmune is a biotechnology company pioneering a novel approach to antibody drug discovery and development. Founded by a world-class, multidisciplinary team of scientists and technologists, Infinimmune is reinventing antibody discovery with an end-to-end platform to deliver antibody drugs derived directly from the human immune system. These truly human antibodies are designed to drug new and existing targets with improved safety and efficacy. Infinimmune will deploy its holistic approach to build its own pipeline of drug candidates and partner with pharmaceutical companies to advance their antibody programs, fill their pipelines, and reach new patients and new indications. To learn more, visit infinimmune.com and follow us on LinkedIn and @infinimmune.

Presentations will highlight the power of Bonum’s proprietary protein engineering technology to generate less toxic, more effective regulated medicines and support clinical development of its lead asset, a conditionally active cLAG3-IL2 SEATTLE--(BUSINESS WIRE)-- Bonum Therapeutics a biotechnology company that is using its proprietary platform for conditional regulation to create highly active and less toxic medicines, today announced that it will present data on a new class of protein therapeutics with the potential for increased safety and efficacy in a wide range of biologic targets and disease areas. Scientists from Bonum will present two posters at the upcoming Keystone Symposium, “Antibodies as Drugs: The Art in Antibody Engineering,” which will be held May 5-8 at the Beaver Run Conference Center in Breckenridge, CO. “We are excited about the success of our platform technology with multiple conditionally active target/effector combinations, and we are particularly encouraged by the rapid progress of our lead program, cLAG3-IL2,” said John Mulligan, PhD, Bonum’s CEO and founder. “These presentations detail the strengths of Bonum’s platform technology and its application to the company’s lead asset.” Details of the poster presentations are as follows: Title: “Development of a new class of targeted and conditional cytokine therapeutics using a novel dual-binding antibody-based platform.” Abstract: This poster will highlight Bonum’s unique dual-binding antibody platform technology which allows the generation of therapeutics with targeted, conditional cytokine activity only when bound to a selected marker. While the company’s current focus is on the development of therapeutics incorporating immunostimulatory cytokines, its technology can be applied to the regulation of any functional protein moieties, including agonist and antagonistic antibody binding domains, growth factors, and receptors. Title: “A novel method for generating regulated cytokine therapeutics: Safety and activity of a conditionally active cLAG3-IL2 in a simple antibody format.” Abstract: This poster will highlight a conditionally active therapeutic called cLAG3-IL2, which targets IL-2 to LAG-3+ cells while remaining systemically inert, even at high treatment doses. The in vivo safety and efficacy data described in this poster demonstrate that this program is suitable for clinical development. The conference organizers have selected Bonum’s poster on its cLAG3-IL2 program for presentation as a short talk during the session “Orchestrating Immune Defense Against Cancer by Antibody Engineering” on May 7 from 8 a.m. to 11 a.m. Dr. Mulligan will give the talk, titled “A novel method for generating regulated cytokine therapeutics: Safety and activity of a conditionally active cLAG3-IL2 in a simple antibody format.” The posters will be available on the Bonum website on Monday, May 6, at noon Mountain Time. Bonum is developing new therapies based on its proprietary platform of conditionally active therapeutics. The company is a spinout of Good Therapeutics, which developed the technology that Bonum is advancing. The merits of the platform were validated by the Roche acquisition of Good Therapeutics for its PD-1-regulated IL-2 program in September 2022. About Bonum Therapeutics Bonum Therapeutics is a privately held biotechnology company focused on the generation of a new class of therapeutics based on a proven technology platform that utilizes principles of regulation to create highly active and less toxic medicines. The company was founded in 2022 as a spinout of Good Therapeutics, following the sale of Good to Roche in September 2022 for $250 million, plus significant milestones. Using a novel approach, Bonum’s molecules combine a sensor component directed against a specific biological marker and a therapeutic component. When the sensor binds its target, the molecule reversibly changes shape and becomes active, delivering potent activity only where it is needed. The technology is applicable to a wide range of therapeutic areas, including oncology, autoimmunity, metabolic disorders, and pain management. Bonum’s initial efforts are focusing on regulated immunocytokines, including conditionally active IFN-alpha, IL-12, and TGF-beta, while it pursues additional applications in partnership with others. The company is backed by a group of leading venture investors including Rivervest Venture Partners, Roche Venture Fund, Digitalis Ventures, American Century Investments, Codon Capital, and Vivo Capital. For more information, please visit our website at and connect with us on LinkedIn and X (Twitter).

Presentation will highlight publicly for the first time preclinical data on Bonum’s lead cLAG3-IL2 program, demonstrating the power of its conditionally active platform. SEATTLE--(BUSINESS WIRE)-- Bonum Therapeutics, a biopharmaceutical company that is using innovative technology for conditional regulation to create highly active and less toxic medicines, today announced the first public presentation of preclinical data on its lead program, a conditionally active LAG3-IL2 therapeutic. Scientists from Bonum will present these data in a poster at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10 in San Diego, CA. Presentation details are as follows: Abstract Title: “A novel method for generating regulated cytokine therapeutics: Safety and activity of a conditionally active cLAG3-IL2 capable of delivering IL2 to LAG3+ cells while remaining inert on LAG3- cells.” Presenter: Justin Killebrew, PhD, Senior Director, Immuno-Oncology Discovery at Bonum Therapeutics Abstract Number: 4062 Date/Time: Tuesday, April 9, 2024, 9:00 AM - 12:30 PM PT Session Title: Immune Modulation with Cytokines The poster presentation will highlight a conditionally active therapeutic called cLAG3-IL2 that targets IL-2 to LAG3+ cells while remaining systemically inert, even at high treatment doses. The in vivo safety and efficacy data described in the poster demonstrate that this program is suitable for progressing into the clinic. John Mulligan, PhD, Bonum Therapeutics’ CEO, commented, “We are excited with the progress of our lead program, cLAG3-IL2, and are eager to make the first public presentation about the program at AACR.” The poster will be available on the Bonum website on the day of the presentation. Bonum is developing new therapies based on its proprietary platform of conditionally active therapeutics. The company is a spinout of Good Therapeutics, which developed the technology that Bonum is advancing. The merits of the platform were validated by the Roche acquisition of Good Therapeutics and its PD-1-regulated IL-2 program in September 2022. Bonum’s core platform enables the engineering and development of a broad array of important medicines. Initially, Bonum is applying the technology to regulated cytokines, including IL-12, IFN-alpha, and TGF-beta for immuno-oncology applications. In parallel, it is seeking partners for applications of its technology in other disease areas where the partner brings expertise in a specific biology and can help guide choices to create new therapies and reach patients as quickly as possible. About Bonum Therapeutics Bonum Therapeutics is a privately held biotechnology company focused on the generation of a new class of therapeutics based on a proven technology platform that utilizes principles of allosteric regulation to create highly active and less toxic medicines. The company was founded in 2022 as a spinout of Good Therapeutics, following the sale of Good to Roche in September 2022 for $250 million, plus significant milestones. Using a novel approach, Bonum’s molecules combine a sensor component directed against a specific biological marker and a therapeutic component. When the sensor binds its target, the molecule reversibly changes shape and becomes active, delivering potent activity only where it is needed. The technology is applicable to a wide range of therapeutic areas, including oncology, autoimmunity, metabolic disorders, and pain management. Bonum’s initial efforts are focusing on regulated immunocytokines, including conditionally active IFN-alpha, IL-12, and TGF-beta, while it pursues additional applications in partnership with others. The company is backed by a group of leading venture investors including Rivervest Venture Partners, Roche Venture Fund, Digitalis Ventures, American Century Investments, Codon Capital, and Vivo Capital. For more information, please visit our website at and connect with us on LinkedIn and X (Twitter). View source version on businesswire.com: Contacts Bonum Contact: Neela Patel, PhD Bonum Therapeutics (425) 375-5369 patel@bonumtx.com Source: Bonum Therapeutics View this news release online at: